BlackRock Advisors’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q3 | – | Sell |
-125,731
| Closed | -$1.88M | – | 3797 |
|
|
2016
Q2 | $1.88M | Buy |
125,731
+89,307
| +245% | +$1.15M | ﹤0.01% | 1459 |
|
|
2016
Q1 | $443K | Buy |
36,424
+1,081
| +3% | +$15.2K | ﹤0.01% | 2139 |
|
|
2015
Q4 | $562K | Sell |
35,343
-23,601
| -40% | -$372K | ﹤0.01% | 2021 |
|
|
2015
Q3 | $904K | Sell |
58,944
-113,591
| -66% | -$2.46M | ﹤0.01% | 1760 |
|
|
2015
Q2 | $4.19M | Buy |
172,535
+87,288
| +102% | +$2.09M | ﹤0.01% | 1045 |
|
|
2015
Q1 | $1.98M | Buy |
85,247
+3,952
| +5% | +$105K | ﹤0.01% | 1234 |
|
|
2014
Q4 | $2.04M | Buy |
81,295
+68,452
| +533% | +$2.01M | ﹤0.01% | 1194 |
|
|
2014
Q3 | $399K | Sell |
12,843
-271
| -2% | -$7.34K | ﹤0.01% | 2145 |
|
|
2014
Q2 | $339K | Sell |
13,114
-286
| -2% | -$6.35K | ﹤0.01% | 2300 |
|
|
2014
Q1 | $313K | Sell |
13,400
-1,655
| -11% | -$36.2K | ﹤0.01% | 2374 |
|
|
2013
Q4 | $382K | Sell |
15,055
-99,043
| -87% | -$2.24M | ﹤0.01% | 2241 |
|
|
2013
Q3 | $2.33M | Buy |
114,098
+29,750
| +35% | +$662K | ﹤0.01% | 1129 |
|
|
2013
Q2 | $1.77M | Buy |
+84,348
| New | +$1.51M | ﹤0.01% | 1155 |
|
BlackRock Advisors's SGNT Position: Q3 2016 in Review
BlackRock Advisors sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2016, closing a stake of 125,731 shares — an estimated $1.88M sold.
BlackRock Advisors first reported a position in SGNT in Q2 2013 and held it in 13 quarters. The position peaked at $4.19M in Q2 2015. 0 funds tracked by Wall St. Rank hold SGNT as of Q3 2016.
- BlackRock Advisors reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2016 after selling out during the quarter.
- BlackRock Advisors sold 125,731 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2016, an estimated $1.88M.
- BlackRock Advisors first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 13 quarters.
- BlackRock Advisors's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $4.19M in Q2 2015.
- 0 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2016.
Based on BlackRock Advisors's 13F filing for Q3 2016, filed 8 Nov 2016.